Warren Center For Neuroscience Drug Discovery

In this episode of Quantum Potential, Craig Lindsley, William K. Warren, Jr. Professor of Medicine, University Distinguished Professor of Biochemistry, Chemistry and Pharmacology and executive director of the Warren Center for Neuroscience Drug Discovery, joins Provost C. Cybele Raver to discuss transformative research exploring how subtle tweaks to brain chemistry could change the way we treat neurodegenerative diseases and chronic pain. Read More

Internal grant programs at Vanderbilt—developed by Chancellor Daniel Diermeier, Provost C. Cybele Raver and Vice Provost for Research and Innovation and Chief Research Officer Padma Raghavan—are accelerating discovery of solutions for real-world challenges. Read More

Recent research from the Warren Center for Neuroscience Drug Discovery, published in the Journal of Medicinal Chemistry, resulted in the proposal of a novel target and mechanism for improving cognition—a negative symptom—while also treating positive symptoms of the disease. Read More

Vanderbilt’s Carrie K. Jones and the University of Glasgow’s Andrew Tobin have received a prestigious £5 million ($6.2 million) Wellcome Trust Discovery Award to study how blocking the M5 muscarinic receptor in the brain could reduce opioid addiction while preserving pain relief. This groundbreaking international collaboration, supported by the Warren Center for Neuroscience Drug Discovery, aims to advance new treatments in the critical global health crisis of opioid use disorder. Read More

We often think about diseases in terms of the symptoms they present. A cold might give you the sniffles or even GI distress, while malaria can give you fever, chills, or nausea... Read More

Tennessee faces a persistent opioid epidemic, with an estimated 70,000 residents affected and the state ranking among the highest for prescription drug misuse. As the crisis evolves, researchers are increasingly turning to neuroscience to better understand the roots of addiction and develop safer, non-addictive pain treatments that could help prevent future overdose deaths. Read More

Researchers at the Warren Center for Neuroscience Drug Discovery have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More

AdvancED spent it's first official year leveraging the collaborative potential of three university functions: online and lifelong learning, pedagogical support and educational technology. Look back at 2024's successes and milestones. Read More

The Center for Technology Transfer and Commercialization has honored five faculty members as 2024 Master Innovators for their groundbreaking research and transformative innovations. These pioneers, recognized for achievements spanning patents, startups and impactful technologies, exemplify Vanderbilt's dedication to translating academic excellence into societal advancements. Read More

The Dare to Grow campaign, which was launched publicly in spring 2023, has eclipsed its $3.2 billion fundraising goal 20 months ahead of its target date of June 30, 2026, underscoring the generosity of donors, widespread enthusiasm for the university’s vision and boundless potential for the future. The news is both a celebration and a call to action as Vanderbilt looks ahead to deepening its impact in Nashville, across the nation and around the world. Read More

Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read More

See some of the bold and collaborative actions Vanderbilt University accomplished this year an innovator and leader in solving the world’s most pressing challenges. Read More

On October 17, 2022, Vanderbilt University launched “Discovery Vanderbilt” to embolden faculty, students and staff to pursue innovative ideas through disciplined, rigorous inquiry. Led by Provost Cybele Raver, the university committed $80 million in the effort—and invested $50 million in the first year alone. Read More

Join the next Lab-to-Table conversation, “Beyond Addiction: Therapeutic Developments and Societal Impact” on Jan. 24 at 11:30 a.m. CT. Read More

The School of Medicine Basic Sciences and the Office of the Vice Provost for Research and Innovation launch the Innovation Ignition Fund. This pilot program offers up to $500,000 in funding and drug development mentorship from Vanderbilt scientists with expertise in translational research. Read More

In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials.     Read More

Vanderbilt has announced the addition of the Warren Center for Neuroscience Drug Discovery into Discovery Vanderbilt as well as an initiative within the Dare to Grow campaign to inspire philanthropy with a one-to-one match for gifts of $100,000 or more. Read More

Biomedical engineer David Merryman and Warren Center for Neuroscience Drug Discovery director Craig Lindsley have developed a new drug that treats PAH, a type of high blood pressure that affects arteries in the lungs and in the heart, without serious neurological side effects. Read More